logo
Plus   Neg
Share
Email

Merck: Phase III JAVELIN Lung 200 Trial With Avelumab Fails To Meet Endpoint

Merck KGaA (MKGAY.PK) and Pfizer Inc. (PFE) announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer whose disease progressed after treatment with a platinum-containing doublet therapy. The company said, while the trial did not meet its prespecified endpoint of improving overall survival in patients with programmed death ligand-1-positive tumors, the proportion of patients in the chemotherapy arm crossing over to immune checkpoint inhibitors outside the study was higher than previously reported in post-platinum immunotherapy clinical trials, and this may have confounded the trial outcome.

The company said the safety profile for avelumab in the trial was consistent with that observed in the overall JAVELIN clinical development program; no new safety signals were identified.

"When the primary endpoint is not met, statistical significance cannot be formally claimed with the predefined statistical significance level. In this circumstance, the Type I error is not strictly controlled and the p-value should be interpreted cautiously," the company said.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Alibaba's founder and chairman Jack Ma has said that the Chinese e-commerce giant no longer plans to create 1 million jobs in the US, citing the ongoing trade conflict between the US and China as the reason. "The promise was made on the premise of friendly US-China partnership and rational trade relations,"... California's insurance regulator has filed a lawsuit against AbbVie Inc. for allegedly giving illegal kickbacks to health care providers to prescribe its arthritis drug Humira. The lawsuit filed in Alameda County Superior Court by the California Department of Insurance alleges that private insurers have paid out $1.2 billion in Humira-related pharmacy claims. Danske Bank A/S's Chief Executive Thomas Borgen resigned on Wednesday after the Danish lender announced the results of an internal probe relating to a money-laundering scandal in its branch in Estonia that involved payments of about 200 billion euros. Danske Bank said its investigation covered about 15,000 customers and a total of around 9.5 million payments through the branch.
Follow RTT